THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Robert Mannel to Neoplasm Recurrence, Local

Back to Details
This is a "connection" page, showing publications Robert Mannel has written about Neoplasm Recurrence, Local.
Robert Mannel
Connection Strength
4.261
Neoplasm Recurrence, Local
  1. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 11 14; 381(20):1929-1939.
    View in: PubMed
    Score: 0.561
  2. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 06; 18(6):779-791.
    View in: PubMed
    Score: 0.470
  3. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2010 Mar; 116(3):332-4.
    View in: PubMed
    Score: 0.281
  4. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. Gynecol Oncol. 2004 Oct; 95(1):157-64.
    View in: PubMed
    Score: 0.197
  5. Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. J Clin Oncol. 2024 Jul 10; 42(20):2425-2435.
    View in: PubMed
    Score: 0.191
  6. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49.
    View in: PubMed
    Score: 0.166
  7. Cisplatin and pentoxifylline in advanced or recurrent squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Oct; 79(1):64-6.
    View in: PubMed
    Score: 0.149
  8. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2020 10; 159(1):79-87.
    View in: PubMed
    Score: 0.147
  9. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2019 03; 152(3):548-553.
    View in: PubMed
    Score: 0.132
  10. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 12; 147(3):648-653.
    View in: PubMed
    Score: 0.121
  11. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Ann Oncol. 2017 May 01; 28(5):996-1004.
    View in: PubMed
    Score: 0.118
  12. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Ann Oncol. 2017 03 01; 28(3):505-511.
    View in: PubMed
    Score: 0.116
  13. A phase II trial of edatrexate in previously treated squamous cell cervical cancer: a Gynecologic Oncology Group study. Am J Clin Oncol. 1997 Feb; 20(1):78-80.
    View in: PubMed
    Score: 0.116
  14. A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):44-8.
    View in: PubMed
    Score: 0.097
  15. Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol. 2014 Sep 01; 32(25):2744-9.
    View in: PubMed
    Score: 0.097
  16. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):38-43.
    View in: PubMed
    Score: 0.097
  17. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jun; 129(3):486-94.
    View in: PubMed
    Score: 0.088
  18. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):86-91.
    View in: PubMed
    Score: 0.087
  19. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb; 14(2):134-40.
    View in: PubMed
    Score: 0.087
  20. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012 Mar; 124(3):569-74.
    View in: PubMed
    Score: 0.080
  21. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2011 Jul; 122(1):89-94.
    View in: PubMed
    Score: 0.078
  22. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61.
    View in: PubMed
    Score: 0.077
  23. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
    View in: PubMed
    Score: 0.074
  24. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Nov; 115(2):215-20.
    View in: PubMed
    Score: 0.069
  25. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol Oncol. 2008 Oct; 111(1):22-6.
    View in: PubMed
    Score: 0.065
  26. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2008 Mar; 108(3):493-9.
    View in: PubMed
    Score: 0.062
  27. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006 Mar; 100(3):586-90.
    View in: PubMed
    Score: 0.053
  28. Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study. Gynecol Oncol. 2005 Mar; 96(3):810-7.
    View in: PubMed
    Score: 0.051
  29. Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe. Gynecol Oncol. 2022 10; 167(1):3-10.
    View in: PubMed
    Score: 0.043
  30. Nodal distribution and its significance in FIGO stage IIIc endometrial cancer. Gynecol Oncol. 2001 Aug; 82(2):375-9.
    View in: PubMed
    Score: 0.040
  31. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001 May; 81(2):273-8.
    View in: PubMed
    Score: 0.039
  32. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. Am J Clin Oncol. 2000 Aug; 23(4):355-7.
    View in: PubMed
    Score: 0.037
  33. Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study. Br J Cancer. 2018 01; 118(2):162-170.
    View in: PubMed
    Score: 0.031
  34. A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep; 138(3):507-12.
    View in: PubMed
    Score: 0.026
  35. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Oct; 127(1):70-4.
    View in: PubMed
    Score: 0.021
  36. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012 Mar 01; 30(7):695-700.
    View in: PubMed
    Score: 0.020
  37. Management of endometrial cancer with suspected cervical involvement. Obstet Gynecol. 1990 Jun; 75(6):1016-22.
    View in: PubMed
    Score: 0.018
  38. Treatment of advanced and recurrent endometrial carcinoma: correlation of patient response to hormonal and cytotoxic chemotherapy and the response predicted by the subrenal capsule chemosensitivity assay. Gynecol Oncol. 1989 Jan; 32(1):55-9.
    View in: PubMed
    Score: 0.017
  39. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007 Nov; 107(2):177-85.
    View in: PubMed
    Score: 0.015
  40. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol. 2004 Oct; 95(1):70-6.
    View in: PubMed
    Score: 0.012
  41. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998 Dec 01; 42(5):1015-23.
    View in: PubMed
    Score: 0.008
  42. Surgical treatment of unexpected invasive cervical cancer found at total hysterectomy. Obstet Gynecol. 1992 Dec; 80(6):931-4.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES